BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA OKs BD Medical's BD PhaSeal™ System


1/15/2013 8:26:39 AM

FRANKLIN LAKES, N.J., Jan. 15, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the BD PhaSeal Closed System Transfer Device (CSTD) under the newly created ONB code. The BD PhaSeal System is the first and only cleared CSTD under the new code, which was created for devices that have specific indications for use with antineoplastic and other hazardous drugs.

The FDA clearance was based on three criteria: no escape of hazardous drug or vapor concentration, no transfer of environmental contaminants, and prevention of microbial ingress. The BD PhaSeal System is the only CSTD currently available that meets all three of these standards.

"Given BD's commitment to creating a safe working environment for healthcare workers, we're pleased at the FDA's clearance of the BD PhaSeal System under the new ONB code. It reinforces our ability to protect healthcare workers from exposure to hazardous drugs," said William A. Tozzi, President, BD Medical Medical Surgical Systems. "The BD PhaSeal System exemplifies our goal of enabling healthcare facilities to reduce workplace hazards and exceed compliance standards while providing quality patient care."

The FDA created the new ONB code because it recognized that a new product code would be in the best interest of public health and wanted to improve the information available to users of devices that have specific indications for use with antineoplastic and other hazardous drugs. The BD PhaSeal System obtained ONB clearance through validated third-party evidence. Please visit www.bd.com/PhaSeal for more information.

About the BD PhaSeal System
The BD PhaSeal System is a closed system transfer device (CSTD) that reduces healthcare workers' exposure to hazardous, parenteral medications from preparation in the pharmacy to administration with the patient. The BD PhaSeal System is an airtight and leak-proof CSTD that mechanically prohibits the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system, thereby minimizing individual and environmental exposure to drug vapor aerosols and spills. The BD PhaSeal System also prevents microbial ingress. With a limited number of components and only one connection interface, the BD PhaSeal System dimensions are created to ISO standards to be compatible with all standard size drug vials and tubing.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Abigail Cardona
BD Public Relations
201-847-4605
abigail_cardona@bd.com

SOURCE BD-Becton Dickinson



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES